Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 17/20 | 0.35 |
| ▸ | HRH1 | P35367 | 17/20 | 0.35 |
| ▸ | HTR2B | P41595 | 14/20 | 0.35 |
| ▸ | HTR2C | P28335 | 13/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22493727 | 1.00 | GPR3 (0.36) | GPR3HTR2AHRH1HTR2BHTR2C | |
| SCHEMBL22493728 | 1.00 | GPR3 (0.36) | GPR3HTR2AHRH1HTR2BHTR2C | |
| SCHEMBL31288676 | 0.88 | HSD11B1 (0.37) | GPR3HTR2AHRH1HTR2BHTR2C | |
| SCHEMBL29832724 | 0.88 | HSD11B1 (0.37) | GPR3HTR2AHRH1HTR2BHTR2C | |
| SCHEMBL21855951 | 0.81 | GPR3 (0.40) | GPR3 | |
| SCHEMBL21855950 | 0.81 | GPR3 (0.40) | GPR3 | |
| SCHEMBL21855883 | 0.80 | GPR3 (0.38) | GPR3HTR2AHTR2BHTR2C | |
| SCHEMBL21855882 | 0.80 | GPR3 (0.38) | GPR3HTR2AHTR2BHTR2C | |
| SCHEMBL22493738 | 0.80 | GPR3 (0.38) | GPR3HTR2AHTR2BHTR2C | |
| SCHEMBL22493740 | 0.80 | GPR3 (0.38) | GPR3HTR2AHTR2BHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124453-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-11884664-B2 | Protein tyrosine phosphatase inhibitors | ARRAY BIOPHARMA INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-11634417-B2 | Protein tyrosine phosphatase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20200317665-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884664-B2 | Protein tyrosine phosphatase inhibitors | PPM1A, PPM1F, PPP5C | GPR3 4426/4885HTR2A 4539/4885HRH1 3098/4885 |
| US-20200317665-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | GPR3 4426/4885HTR2A 4539/4885HRH1 3098/4885 |
| US-20240124453-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | GPR3 4426/4885HTR2A 4539/4885HRH1 3098/4885 |
| US-11634417-B2 | Protein tyrosine phosphatase inhibitors | PPM1A, PPM1F, PPP5C | GPR3 4426/4885HTR2A 4539/4885HRH1 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.